Instructions for use Septefril-Darnitsa tablets 0.2 mg No. 40
Composition
active ingredient: decamethoxine;
1 tablet contains decamethoxine 0.2 mg;
excipients: crystalline sugar, calcium stearate.
Dosage form
Pills.
Main physicochemical properties: tablets of white or almost white color, flat-cylindrical shape, with a score and a bevel.
Pharmacotherapeutic group
Drugs used in throat diseases. Various antiseptics. ATX code R02A A20.
Pharmacological properties
Pharmacodynamics
The active substance of the drug - decamethoxin - is a quaternary ammonium compound and belongs to the group of cationic surfactants. Decamethoxin combines with the phosphate groups of lipids of the cytoplasmic membrane of the microbial cell, which leads to a violation of its permeability and destruction.
The drug has a wide spectrum of antimicrobial activity. Active against Staphylococcus spp. (including penicillin-resistant strains of S. aureus), Streptococcus spp., Stomatococcus spp., Corynebacterium spp. (including C. diphtheriae), enterobacteria, pseudomonads, spore-forming microorganisms, protozoa, yeast-like fungi, especially Candida albicans, dermatomycetes, viruses. It has a bactericidal, fungicidal and sporicidal effect, and also inactivates diphtheria exotoxin.
The drug increases the sensitivity of bacteria to antibiotics.
The drug does not suppress the specific and nonspecific immunological reactivity of the human body.
Indication
Local treatment as part of complex therapy for diseases of the oral cavity, pharynx, and larynx (pharyngitis, laryngitis, tonsillitis, gingivitis, periodontitis, stomatitis, candidiasis of the oral mucosa, initial stage of angina); sanitation of the oral cavity, pharynx, and nasopharynx in carriers of pathogenic staphylococcus, diphtheria bacillus, and candida; prevention of infectious complications after surgical interventions in the oral cavity, pharynx, and larynx.
Contraindication
Hypersensitivity to decamethoxine or to other components of the drug.
Interaction with other medicinal products and other types of interactions
When used simultaneously with antibiotics and systemic antimicrobial agents, the antibacterial effect of the drug is enhanced.
Application features
To increase the concentration of the drug in saliva, frequent swallowing of saliva should be avoided during resorption of the drug.
It is undesirable to use the drug simultaneously with various types of mouth and throat rinses.
When using the drug for longer than 7 days, disturbances in the balance of the pharyngeal microflora may occur.
The medicinal product contains crystalline sugar, so patients with diabetes should use the drug with caution.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Use during pregnancy or breastfeeding
There are no clinical data on the safety of the drug during pregnancy or breastfeeding. The drug should not be used during pregnancy. If necessary, breastfeeding should be discontinued.
Method of administration and doses
After rinsing the mouth, place the tablet behind the cheek and keep it in the mouth until completely dissolved. Adults are prescribed 1 tablet.
4-6 times a day. The duration of treatment should not exceed 7 days. The drug should be taken after a meal, then you should refrain from eating and drinking for 1 hour.
Children
There is no clinical experience regarding the safety and efficacy of the drug in children.
Overdose
There were no data on cases of drug overdose.
Adverse reactions
There were no data on cases of drug overdose.
Expiration date
3 years.
Do not use the medicine after the expiry date stated on the packaging.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 tablets in a blister pack; 4 blister packs in a pack.
Vacation category
Without a prescription.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
